Stevanato Group Investor Presentation

Single Value Proposition Delivered Through Two Segments Integrated End-to-End Offering Across Both Segments Stevanato Group's Offering Engineering Biopharmaceutical & Diagnostic Solutions 2023 Revenue: € 879 M (81%) 2023 Revenue: € 206 M (19%) Drug Containment Solutions (DCS) Ready-To-Use EZ-fill® & Bulk SG Pre-filled Vials Cartridges Drug Delivery Systems (DDS) In-Vitro Diagnostics (IVD) Assembly Visual Inspection Packaging & Serialization Glass Converting Market Syringes Leader SG, Stevanato Group Jo Analytical Services Stevanato Group Investor Presentation, March 2024 11

View entire presentation